Cargando…
Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts
Vγ9Vδ2 T cell-based anticancer immunotherapy has shown some promise in early-phase clinical trials but there is still large room for improvement. Using the extracellular domain of the human NKG2D, a stimulatory receptor expressed by Vγ9Vδ2 T cells, we constructed NKG2D ligand-specific chimeric antig...
Autores principales: | Ang, Wei Xia, Ng, Yu Yang, Xiao, Lin, Chen, Can, Li, Zhendong, Chi, Zhixia, Tay, Johan Chin-Kang, Tan, Wee Kiat, Zeng, Jieming, Toh, Han Chong, Wang, Shu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240063/ https://www.ncbi.nlm.nih.gov/pubmed/32462079 http://dx.doi.org/10.1016/j.omto.2020.04.013 |
Ejemplares similares
-
Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy
por: Du, Shou-Hui, et al.
Publicado: (2016) -
Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
por: Zhang, Xi, et al.
Publicado: (2022) -
Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis
por: Ang, Wei Xia, et al.
Publicado: (2017) -
Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL–NKG2D Axis
por: Wang, Zhan, et al.
Publicado: (2018) -
Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity
por: Cimini, Eleonora, et al.
Publicado: (2019)